Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. oncotheranostics

ONCOTHERANOSTICS SIGNED

Advanced Theranostic Nanomedicines for Oncology. Development of new combinatorial therapies for primary and metastatic Breast Cancer.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ONCOTHERANOSTICS project word cloud

Explore the words cloud of the ONCOTHERANOSTICS project. It provides you a very rough idea of what is the project "ONCOTHERANOSTICS" about.

nanomedine    reinforcing    synthesis    breast    incoming    theranostic    techniques    monitor    despite    proposes    completion    safer    effect    cells    mechanisms    biology    downregulation    environment    knocking    multiple    host    treatment    outgoing    interplay    line    multidisciplinary    model    molecular    pacheco    primary    purpose    combinatorial    successful    immunotherapy    treat    death    vivo    surveillance    sirna    multimodal    triggers    metastatic    establishment    nanomedicine    combining    personalizing    personalized    cross    agent    nanoparticle    trained    formulation    uses    2nd    health    genetic    mri    single    escaping    dual    imaging    multifaceted    strategies    oncotheranostics    training    choline    malignancy    expertise    anticipate    boosting    tumor    cutting    immune    natural    globally    invasively    negative    care    competitiveness    personalize    theranostics    dr    tumoral    chemist    treatments    organic    triple    intervention    diagnostic    kinase    transferred    genes    therapies    cancer    rendering    therapeutic    provides   

Project "ONCOTHERANOSTICS" data sheet

The following table provides information about the project.

Coordinator		 AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS 

Organization address
address: CALLE SERRANO 117
city: MADRID
postcode: 28006
website: http://www.csic.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Spain [ES]
 Total cost 257˙191 €
 EC max contribution 257˙191 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-GF
 Starting year 2019
 Duration (year-month-day) from 2019-03-01   to  2022-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS ES (MADRID) coordinator 257˙191.00
2    JOHNS HOPKINS UNIVERSITY US (BALTIMORE) partner 0.00

Map

 Project objective

Despite significant advances in recent years, cancer remains the 2nd cause of death globally. Immunotherapy is an exciting new therapeutic approach that triggers natural immune response against cancer cells. Theranostics is an emerging therapeutic intervention, that uses dual (or multiple) purpose nanomedine, combining diagnostic and therapeutic effects within a single multifaceted formulation. ONCOTHERANOSTICS proposes the use of a novel theranostic agent to target key tumoral genes by siRNA and monitor the impact of the downregulation non-invasively in vivo. Specific aims include understanding the interplay between choline kinase and tumor escaping natural immune surveillance, and to develop new combinatorial therapies in a model of primary and metastatic triple negative breast cancer. We anticipate that successful completion of the project will result in significant advances in personalized tumor treatments, rendering safer strategies to treat cancer with a dual effect; boosting natural immune response and knocking down one of the main mechanisms of malignancy. Dr. Pacheco is an organic chemist with expertise in MRI who will be trained (outgoing) in nanoparticle synthesis, non-MRI imaging techniques and advanced molecular biology/genetic approaches. Training will be transferred to the host European institution (incoming) by the establishment of a new research line in the emerging field of Theranostics. ONCOTHERANOSTICS seeks to improve our understanding of cancer and how to personalize treatments, fostering the development of nanomedicine targeting specific genes in a way that can be assessed non-invasively. ONCOTHERANOSTICS provides a multidisciplinary environment for cancer treatment, involving multifaceted nanomedicine, multimodal molecular imaging and molecular biology/genetic approaches. The proposal directly addresses the cross cutting priority of personalizing health and care established by H2020, reinforcing European competitiveness in cancer research.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ONCOTHERANOSTICS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ONCOTHERANOSTICS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

GrowthDevStability (2020)

Characterization of the developmental mechanisms ensuring a robust symmetrical growth in the bilateral model organism Drosophila melanogaster

Read More  

NarrowbandSSL (2019)

Development of Narrow Band Blue and Red Emitting Macromolecules for Solution-Processed Solid State Lighting Devices

Read More  

RipGEESE (2020)

Identifying the ripples of gene regulation evolution in the evolution of gene sequences to determine when animal nervous systems evolved

Read More